AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) produced a 45.16% rally since recording the worst price of $1.55. Thanks to the latest 5.88% increase, it now trades at $2.25. Throughout the trading on 11/24/2017, the share price floated between $2.1 and $2.25. This company shares are 88.89% off its target price of $4.25 and the current market capitalization stands at $111.89M. The recent change has given its price a -22.31% deficit over SMA 50 and -60.87% deficit over its 52-week high. The stock witnessed 16.88% gains, -23.73% declines and -11.76% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ACRX’s volatility during a week at 4.69% and during a month it has been found around 6.3%.AcelRx Pharmaceuticals, Inc. (ACRX) Top Holders
Institutional investors currently hold around $15 million or 33.6% in ACRX stock. Look at its top three institutional owners. Vanguard Group Inc owns $2.94 million in AcelRx Pharmaceuticals, Inc., which represents roughly 2.63% of the company’s market cap and approximately 19.59% of the institutional ownership. Similar statistics are true for the second largest owner, Perceptive Advisors Llc, which owns 1,244,608 shares of the stock are valued at $2.65 million. The third largest holder is Palo Alto Investors, Llc, which currently holds $2.2 million worth of this stock and that ownership represents nearly 1.96% of its market capitalization.AcelRx Pharmaceuticals, Inc. 13F Filings
At the end of 09/30/2017 reporting period, 25 institutional holders increased their position in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) by some 743,402 shares, 32 decreased positions by 4,429,902 and 13 held positions by 1,729,035. That puts total institutional holdings at 6,902,339 shares, according to SEC filings. The stock grabbed 12 new institutional investments totaling 418,367 shares while 14 institutional investors sold out their entire positions totaling 832,439 shares.AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Insider Trades
Multiple company employees have indulged in significant insider trading. AcelRx Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Edwards Mark G has acquired 30,000 shares of AcelRx Pharmaceuticals, Inc. (ACRX) in trading session dated Nov. 14, 2017. These shares are worth $57,000 and were traded at $1.9 each. The SEC filing shows that Asadorian Raffi performed a purchase of 5,000 shares. The CFO added these shares by way of transaction on Nov. 13, 2017. The company’s shares were assimilated at $1.94 per share worth to an investment of some $9,700 on account of Asadorian Raffi.
Chief Development Officer, Hamel Lawrence G, sold 10,161 common shares of AcelRx Pharmaceuticals, Inc. (ACRX) in the open market. In a transaction dated Oct. 02, 2017, the shares were put up for sale at an average price of $5.29, raking in a sum of $53,752. After this sale, 58,343 common shares of ACRX are directly owned by the insider, with total stake valued at $131,272.
In the transaction dated Sep. 11, 2017, the great number of shares acquired came courtesy the CFO; Asadorian Raffi added a total of 7,000 shares at an average price of $3.24, amounting to approximately $22,680. The insider now directly owns 7,000 shares worth $15,750.AcelRx Pharmaceuticals, Inc. (ACRX) Analyst Guide
Several analysts have released their opinion on AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), with 2 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.17 average brokerage recommendation.